Ophthalmology, Department of Surgery, University of Melbourne, Melbourne, Australia.
Centre for Eye Research Australia, Melbourne, Australia.
JAMA Ophthalmol. 2022 May 1;140(5):486-494. doi: 10.1001/jamaophthalmol.2022.0050.
Diabetic retinopathy (DR) may be worsened by pregnancy in pregnant women with preexisting type 1 diabetes (T1D) or type 2 diabetes (T2D). Conflicting findings from previous studies have resulted in inconsistencies in guidelines regarding DR management in pregnancy. Global estimates of DR prevalence and progression in pregnancy are therefore required to provide clearer information about the overall true burden of DR in this population.
To estimate the prevalence of DR and its progression rate in pregnant women with preexisting T1D or T2D diagnosed before pregnancy.
For this systematic review and meta-analysis, conducted from November 27, 2018, to June 29, 2021, a systematic literature search was conducted in MEDLINE/Ovid, Embase/Ovid, and Scopus databases to identify English-language articles that were published from inception through October 2020.
Observational studies that reported on DR and its changes in pregnant women with preexisting T1D and T2D.
Two independent reviewers extracted relevant data from each included study. Data were pooled using a random-effects model with the Freeman-Tukey double arcsine transformation. This study followed the Meta-analysis of Observational Studies in Epidemiology (MOOSE) reporting guidelines.
Prevalence of any DR, proliferative DR (PDR), and DR progression rates.
A total of 18 observational studies involving 1464 pregnant women with T1D and 262 pregnant women with T2D were included in the analysis. The pooled prevalence of any DR and PDR in early pregnancy was 52.3 (95% CI, 41.9-62.6) and 6.1 (95% CI, 3.1-9.8) per 100 pregnancies, respectively. The pooled progression rate per 100 pregnancies for new DR development was 15.0 (95% CI, 9.9-20.8), worsened nonproliferative DR was 31.0 (95% CI, 23.2-39.2), progression from nonproliferative DR to PDR was 6.3 (95% CI, 3.3-10.0), and worsened PDR was 37.0 (95% CI, 21.2-54.0). DR progression rates per 100 pregnancies were similar between the T1D and T2D groups, except for the development of new DR (T1D groups: 15.8; 95% CI, 10.5-21.9; T2D groups: 9.0; 95% CI, 4.9-14.8). A global trend toward a lower DR progression rate was observed after the 1989 St Vincent Declaration.
Results of this systematic review and meta-analysis suggest that women with T1D and T2D had a similar risk of DR progression during pregnancy. Despite improvements in the management of diabetes and diabetes during pregnancy, DR prevalence and progression in pregnant women with diabetes remains higher than the nonpregnant population with diabetes, highlighting the need to improve DR management in pregnancy.
重要性:妊娠可能会加重患有 1 型糖尿病(T1D)或 2 型糖尿病(T2D)的孕妇的糖尿病视网膜病变(DR)。先前研究的相互矛盾的结果导致了妊娠期间 DR 管理指南的不一致。因此,需要全球估计妊娠期间 DR 的患病率和进展率,以更清楚地了解该人群中 DR 的总体真实负担。
目的:评估孕前诊断的 T1D 或 T2D 孕妇的 DR 患病率及其进展速度。
数据来源:本系统评价和荟萃分析于 2018 年 11 月 27 日至 2021 年 6 月 29 日进行,在 MEDLINE/Ovid、Embase/Ovid 和 Scopus 数据库中进行了系统文献检索,以确定截至 2020 年 10 月发表的关于 DR 及其在患有 T1D 和 T2D 的孕妇中变化的英语文章。
研究选择:报告了患有 T1D 和 T2D 的孕妇的 DR 及其变化的观察性研究。
数据提取和综合:两名独立审查员从每个纳入的研究中提取相关数据。使用随机效应模型和 Freeman-Tukey 双反正弦变换对数据进行了汇总。本研究遵循观察性研究荟萃分析(MOOSE)报告指南。
主要结果和措施:任何 DR、增殖性 DR(PDR)和 DR 进展率的患病率。
结果:共纳入了 18 项涉及 1464 名 T1D 孕妇和 262 名 T2D 孕妇的观察性研究。早期妊娠时任何 DR 和 PDR 的合并患病率分别为 52.3(95%CI,41.9-62.6)和 6.1(95%CI,3.1-9.8)。新 DR 发展的每 100 例妊娠的进展率为 15.0(95%CI,9.9-20.8),非增殖性 DR 恶化率为 31.0(95%CI,23.2-39.2),非增殖性 DR 进展为 PDR 的发生率为 6.3(95%CI,3.3-10.0),PDR 恶化率为 37.0(95%CI,21.2-54.0)。除新 DR 发展外(T1D 组:15.8;95%CI,10.5-21.9;T2D 组:9.0;95%CI,4.9-14.8),T1D 和 T2D 组的 DR 进展率相似。自 1989 年《圣文森特宣言》以来,全球 DR 进展率呈下降趋势。
结论和相关性:本系统评价和荟萃分析的结果表明,T1D 和 T2D 女性在妊娠期间发生 DR 的风险相似。尽管糖尿病和妊娠期间糖尿病的管理有所改善,但患有糖尿病的孕妇的 DR 患病率和进展率仍高于非妊娠糖尿病患者,这突出表明需要改善妊娠期间的 DR 管理。